US Pharma MarketingRoche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The FDA approved the Tecentriq label expansion alongside Natera's Signatera as a companion diagnostic.
Source: FiercePharma